MedXY – Page 10

$Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial$

Clinical Updates Wellness & Lifestyle

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

By MedXY 08/03/2025

The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.

Clinical Updates Wellness & Lifestyle

Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial

By MedXY 08/03/2025

The IMPORT LOW trial confirms that partial-breast and reduced-dose radiotherapy are as effective and safe as whole-breast radiotherapy for selected women with early breast cancer, supporting their use as standard care.

Clinical Updates Wellness & Lifestyle

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

By MedXY 08/03/2025

Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.

Clinical Updates Wellness & Lifestyle

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY 08/03/2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

Clinical Updates Wellness & Lifestyle

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Clinical Updates Wellness & Lifestyle

Zanidatamab Plus Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastro-Oesophageal Adenocarcinoma: Clinical Efficacy and Safety Insights from a Phase 2 Study

By MedXY 08/03/2025

Zanidatamab combined with chemotherapy shows promising efficacy and manageable safety in first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma, with durable responses and improved survival outcomes.

$Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results$

Clinical Updates Wellness & Lifestyle

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

By MedXY 08/02/2025

The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.

Clinical Updates Wellness & Lifestyle

Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland

By MedXY 08/02/2025

The DipGluMo trial found that real-time continuous glucose monitoring does not improve perinatal outcomes versus self-monitoring in gestational diabetes, but is preferred by patients for ease of use.

Clinical Updates Wellness & Lifestyle

Avatrombopag in Pediatric Immune Thrombocytopenia: Evidence from the AVA-PED-301 Phase 3b Trial

By MedXY 08/02/2025

The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.

Clinical Updates Wellness & Lifestyle

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY 08/02/2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.